Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state.

Although the sartan family of angiotensin II type 1 (AT(1)) receptor blockers (ARBs), which includes valsartan, olmesartan, and losartan, have a common pharmacophore structure, their effectiveness in therapy differs. Although their efficacy may be related to their binding strength, this notion has changed with a better understanding of the molecular mechanism. Therefore, we hypothesized that each ARB differs with regard to its molecular interactions with AT(1) receptor in inducing inverse agonism. Interactions between valsartan and residues Ser(105), Ser(109), and Lys(199) were important for binding. Valsartan is a strong inverse agonist of constitutive inositol phosphate production by the wild-type and N111G mutant receptors. Substituted cysteine accessibility mapping studies indicated that valsartan, but not losartan, which has only weak inverse agonism, may stabilize the N111G receptor in an inactive state upon binding. In addition, the inverse agonism by valsatan was mostly abolished with S105A/S109A/K199Q substitutions in the N111G background. Molecular modeling suggested that Ser(109) and Lys(199) bind to phenyl and tetrazole groups of valsartan, respectively. Ser(105) is a candidate for binding to the carboxyl group of valsartan. Thus, the most critical interaction for inducing inverse agonism involves transmembrane (TM) V (Lys(199)) of AT(1) receptor although its inverse agonist potency is comparable to olmesartan, which bonds with TM III (Tyr(113)) and TM VI (His(256)). These results provide new insights into improving ARBs and development of new G protein-coupled receptor antagonists.

[1]  J. Thevelein,et al.  Glucose and sucrose act as agonist and mannose as antagonist ligands of the G protein-coupled receptor Gpr1 in the yeast Saccharomyces cerevisiae. , 2004, Molecular cell.

[2]  X. P. Liu,et al.  The active state of the AT1 angiotensin receptor is generated by angiotensin II induction. , 1996, Biochemistry.

[3]  S. Miura,et al.  Mechanism of constitutive activation of the AT1 receptor: influence of the size of the agonist switch binding residue Asn(111). , 1998, Biochemistry.

[4]  K. Catt,et al.  International union of pharmacology. XXIII. The angiotensin II receptors. , 2000, Pharmacological reviews.

[5]  H. Ohta,et al.  Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure. , 2001, Hypertension research : official journal of the Japanese Society of Hypertension.

[6]  S. Miura,et al.  Molecular analysis of the structure and function of the angiotensin II type 1 receptor. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[7]  David S. Goodsell,et al.  Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4 , 1996, J. Comput. Aided Mol. Des..

[8]  R. Alonso,et al.  pK(a) determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry. , 2001, Journal of pharmaceutical and biomedical analysis.

[9]  Keita Noda,et al.  “Network Leaning” as a Mechanism of Insurmountable Antagonism of the Angiotensin II Type 1 Receptor by Non-peptide Antagonists* , 2004, Journal of Biological Chemistry.

[10]  S. Miura,et al.  Constitutive Activation of Angiotensin II Type 1 Receptor Alters the Orientation of Transmembrane Helix-2* , 2002, The Journal of Biological Chemistry.

[11]  R. Graham,et al.  Phe(303) in TMVI of the alpha(1B)-adrenergic receptor is a key residue coupling TM helical movements to G-protein activation. , 2002, Biochemistry.

[12]  H Weinstein,et al.  Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor , 1997, The EMBO journal.

[13]  S. Miura,et al.  TM2-TM7 Interaction in Coupling Movement of Transmembrane Helices to Activation of the Angiotensin II Type-1 Receptor* , 2003, The Journal of Biological Chemistry.

[14]  P. Corvol,et al.  Effect of Reduced Angiotensin-Converting Enzyme Gene Expression and Angiotensin-Converting Enzyme Inhibition on Angiotensin and Bradykinin Peptide Levels in Mice , 2004, Hypertension.

[15]  S. Kudoh,et al.  Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II , 2004, Nature Cell Biology.

[16]  Dennis A Dougherty,et al.  Cation-pi interactions in ligand recognition and catalysis. , 2002, Trends in pharmacological sciences.

[17]  D. A. Dougherty,et al.  From ab initio quantum mechanics to molecular neurobiology: a cation-pi binding site in the nicotinic receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  E. Cesarman,et al.  G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator , 1998, Nature.

[19]  Cation-π versus OH-π Interactions in Proteins: A Density Functional Study , 2000 .

[20]  L. Gnudi,et al.  Interaction of Angiotensin Ii and Mechanical Stretch on Vascular Endothelial Growth Factor Production by Human Mesangial Cells , 2022 .

[21]  S. Miura,et al.  Role of Aromaticity of Agonist Switches of Angiotensin II in the Activation of the AT1 Receptor* , 1999, The Journal of Biological Chemistry.

[22]  S. Karnik,et al.  The Docking of Arg2 of Angiotensin II with Asp281 of AT1 Receptor Is Essential for Full Agonism (*) , 1995, The Journal of Biological Chemistry.

[23]  G. Flesch,et al.  Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man , 1997, European Journal of Clinical Pharmacology.

[24]  I. Komuro,et al.  Molecular Mechanism Underlying Inverse Agonist of Angiotensin II Type 1 Receptor* , 2006, Journal of Biological Chemistry.

[25]  J. Gallivan,et al.  Can lone pairs bind to a pi system? The water...hexafluorobenzene interaction. , 1999, Organic letters.

[26]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .

[27]  H. Khorana,et al.  Requirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin , 1996, Science.

[28]  S. Miura,et al.  Constitutively Active Homo-oligomeric Angiotensin II Type 2 Receptor Induces Cell Signaling Independent of Receptor Conformation and Ligand Stimulation* , 2005, Journal of Biological Chemistry.

[29]  R. Graham,et al.  Tetrazole and Carboxylate Groups of Angiotensin Receptor Antagonists Bind to the Same Subsite by Different Mechanisms (*) , 1995, The Journal of Biological Chemistry.

[30]  E. Cesarman,et al.  Erratum: G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator , 1998, Nature.

[31]  L. Pardo,et al.  Linking agonist binding to histamine H1 receptor activation , 2005, Nature chemical biology.